{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:56:13Z","timestamp":1792036573279,"version":"4.4.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic lymphocytic leukemia (CLL) is the most common type of leukemia among US adults and has experienced a rapidly evolving treatment landscape; yet current data on treatment patterns in clinical practice and economic burden are limited. This study aimed to provide an up-to-date description of real-world characteristics, treatments, and costs of patients with CLL or small lymphocytic lymphoma (SLL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Using retrospective data from the Optum Clinformatics DataMart database (January 2013 to December 2021), adults with diagnosis codes for CLL\/SLL on two different dates were selected. An adapted algorithm identified lines of therapy (LOT). Treatment patterns were stratified by the index year pre- and post-2018. Healthcare resource utilization and costs were evaluated per patient-years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 18 418 patients with CLL\/SLL were identified, 5226 patients (28%) were treated with \u22651 LOT and 1728 (9%) with \u22652 LOT. Among patients diagnosed with CLL in 2014-2017 and \u22651 LOT (N\u2005=\u20052585), 42% used targeted therapy and 30% used chemoimmunotherapy in first line (1L). The corresponding proportions of patients diagnosed with CLL in 2018-2021 (N\u2005=\u20052641) were 54% and 16%, respectively. Total costs were numerically 3.5 times higher and 4.9 times higher compared with baseline costs among patients treated with 1L+ and 3L+, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study documented the real-world change in CLL treatment landscape and the substantial economic burden of patients with CLL\/SLL. Specifically, targeted therapies were increasingly used as 1L treatments and they were part of more than half of 1L regimens in recent years (2018-2021).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad324","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T12:22:13Z","timestamp":1706358133000},"page":"e360-e371","source":"Crossref","is-referenced-by-count":22,"title":["Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US"],"prefix":"10.1093","volume":"29","author":[{"given":"Xiaoqin","family":"Yang","sequence":"first","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Zanardo","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Denver, CO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lejeune","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e , Montr\u00e9al, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"De Nigris","sequence":"additional","affiliation":[{"name":"MSD (UK) Limited , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sarpong","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e , Montr\u00e9al, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"key":"2024030500080493700_CIT0001","first-page":"16096","article-title":"Chronic lymphocytic leukaemia","volume-title":"Nat Rev Dis Primers","author":"Kipps","year":"2017"},{"key":"2024030500080493700_CIT0002","first-page":"103","article-title":"Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients","volume-title":"Eur J Cancer","author":"Visentin","year":"2017"},{"key":"2024030500080493700_CIT0003","first-page":"7","article-title":"Cancer statistics, 2021","volume-title":"CA Cancer J Clin","author":"Siegel","year":"2021"},{"key":"2024030500080493700_CIT0004","first-page":"2205","article-title":"Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies","volume-title":"Haematologica","author":"Delgado","year":"2020"},{"key":"2024030500080493700_CIT0005","first-page":"1910","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume-title":"N Engl J Med","author":"D\u00f6hner","year":"2000"},{"key":"2024030500080493700_CIT0006","first-page":"1266","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume-title":"Am J Hematol","author":"Hallek","year":"2019"},{"key":"2024030500080493700_CIT0007","first-page":"743","article-title":"Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading","volume-title":"Expert Rev Hematol","author":"Doubek","year":"2015"},{"key":"2024030500080493700_CIT0008","first-page":"460","article-title":"Treatment of chronic lymphocytic leukemia","volume-title":"N Engl J Med","author":"Burger","year":"2020"},{"key":"2024030500080493700_CIT0009","first-page":"208","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume-title":"Blood","author":"Fischer","year":"2016"},{"key":"2024030500080493700_CIT0010","first-page":"1164","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume-title":"Lancet","author":"Hallek","year":"2010"},{"key":"2024030500080493700_CIT0011","first-page":"1101","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume-title":"N Engl J Med","author":"Goede","year":"2014"},{"key":"2024030500080493700_CIT0012","first-page":"1873","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume-title":"Lancet","author":"Hillmen","year":"2015"},{"key":"2024030500080493700_CIT0013","first-page":"69","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume-title":"J Hematol Oncol","author":"Patel","year":"2021"},{"key":"2024030500080493700_CIT0014","volume-title":"Prescribing Information (October 2021)","author":"VENCLEXTA (venetoclax)"},{"key":"2024030500080493700_CIT0015","first-page":"396","article-title":"Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease","volume-title":"Cancer J","author":"Santos","year":"2012"},{"key":"2024030500080493700_CIT0016","first-page":"2375","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume-title":"Blood","author":"Swerdlow","year":"2016"},{"key":"2024030500080493700_CIT0017","first-page":"79","article-title":"Ibrutinib combinations in CLL therapy: scientific rationale and clinical results","volume-title":"Blood Cancer J","author":"Timofeeva","year":"2021"},{"key":"2024030500080493700_CIT0018","first-page":"2425","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume-title":"N Engl J Med","author":"Burger","year":"2015"},{"key":"2024030500080493700_CIT0019","first-page":"213","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume-title":"N Engl J Med","author":"Byrd","year":"2014"},{"key":"2024030500080493700_CIT0020","first-page":"3918","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume-title":"Clin Cancer Res","author":"Byrd","year":"2020"},{"key":"2024030500080493700_CIT0021","first-page":"17","article-title":"Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma","volume-title":"Biomark Res","author":"Zhang","year":"2022"},{"key":"2024030500080493700_CIT0022","first-page":"3441","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume-title":"J Clin Oncol","author":"Byrd","year":"2021"},{"key":"2024030500080493700_CIT0023","first-page":"1553","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume-title":"Blood Adv","author":"Awan","year":"2019"},{"key":"2024030500080493700_CIT0024","first-page":"2364","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume-title":"Haematologica","author":"Rogers","year":"2021"},{"key":"2024030500080493700_CIT0025","first-page":"319","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume-title":"N Engl J Med","author":"Brown","year":"2023"},{"key":"2024030500080493700_CIT0026","first-page":"2040620721989588","article-title":"The evolving role of Bruton\u2019s tyrosine kinase inhibitors in chronic lymphocytic leukemia","volume-title":"Ther Adv Hematol","author":"Gordon","year":"2021"},{"key":"2024030500080493700_CIT0027","first-page":"61","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume-title":"Blood","author":"Liu","year":"2015"},{"key":"2024030500080493700_CIT0028","first-page":"80","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume-title":"JAMA Oncol","author":"Maddocks","year":"2015"},{"key":"2024030500080493700_CIT0029","first-page":"641","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume-title":"Blood","author":"Quinquenel","year":"2019"},{"key":"2024030500080493700_CIT0030","first-page":"2286","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume-title":"N Engl J Med","author":"Woyach","year":"2014"},{"key":"2024030500080493700_CIT0031","first-page":"1437","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume-title":"J Clin Oncol","author":"Woyach","year":"2017"},{"issue":"Supplement_1","key":"2024030500080493700_CIT0032","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to acalabrutinib in CLL Is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"key":"2024030500080493700_CIT0033","first-page":"169","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume-title":"Lancet Oncol","author":"Farooqui","year":"2015"},{"key":"2024030500080493700_CIT0034","first-page":"169","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL) \u2013 a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume-title":"Leukemia","author":"Al-Sawaf","year":"2021"},{"key":"2024030500080493700_CIT0035","first-page":"765","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume-title":"Haematologica","author":"Wang","year":"2020"},{"key":"2024030500080493700_CIT0036","first-page":"630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume-title":"Front Cell Dev Biol","author":"Estupi\u00f1\u00e1n","year":"2021"},{"key":"2024030500080493700_CIT0037","first-page":"166","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume-title":"J Clin Oncol","author":"Chen","year":"2017"},{"key":"2024030500080493700_CIT0038","first-page":"418","article-title":"Cost-effectiveness of new targeted agents in the treatment of chronic lymphocytic leukemia","volume-title":"Cancer J","author":"Harkins","year":"2019"},{"key":"2024030500080493700_CIT0039","first-page":"252","article-title":"Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels","volume-title":"J Oncol Pract","author":"Shanafelt","year":"2015"},{"key":"2024030500080493700_CIT0040","first-page":"e18065","article-title":"Economic burden of relapsed\/refractory chronic lymphocytic leukemia","volume-title":"J Clin Oncol","author":"Guerin","year":"2015"},{"key":"2024030500080493700_CIT0041","first-page":"3129","article-title":"Real-world treatment patterns, adverse events, resource use, and costs among commercially insured, younger patients with chronic lymphocytic leukemia in the USA: a retrospective cohort study","volume-title":"Adv Ther","author":"Kabadi","year":"2020"},{"key":"2024030500080493700_CIT0042","first-page":"576","article-title":"Overall survival and health care costs of Medicare patients with previously treated chronic lymphocytic leukemia","volume-title":"J Cancer Ther","author":"Reyes","year":"2018"},{"key":"2024030500080493700_CIT0043","first-page":"763","article-title":"Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy","volume-title":"Clin Lymphoma Myeloma Leuk","author":"Emond","year":"2019"},{"key":"2024030500080493700_CIT0044","first-page":"2009","article-title":"Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia","volume-title":"Curr Med Res Opin","author":"Huang","year":"2020"},{"issue":"Supplement_1","key":"2024030500080493700_CIT0045","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2019-122054","article-title":"Utilization and early discontinuation of first-line ibrutinib for patients with chronic lymphocytic leukemia treated in the community oncology setting in the United States","volume":"134","author":"Huntington","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2024030500080493700_CIT0046","first-page":"5350","article-title":"Disease progression on ibrutinib therapy is associated with a poor clinical outcome in chronic lymphocytic leukemia (CLL) patients managed in standard clinical practice","volume":"130","author":"Akhtar","year":"2017","journal-title":"Blood"},{"key":"2024030500080493700_CIT0047","first-page":"2712","article-title":"Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice","volume-title":"Leuk Lymphoma","author":"Hampel","year":"2019"},{"key":"2024030500080493700_CIT0048","first-page":"874","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume-title":"Haematologica","author":"Mato","year":"2018"},{"key":"2024030500080493700_CIT0049","first-page":"66","article-title":"Ibrutinib dose modifications in the management of CLL","volume-title":"J Hematol Oncol","author":"Hardy-Abeloos","year":"2020"},{"key":"2024030500080493700_CIT0050","first-page":"636","article-title":"Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies","volume-title":"Cancer Biol Ther","author":"Mato","year":"2018"},{"key":"2024030500080493700_CIT0051","first-page":"65","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume-title":"Lancet Oncol","author":"Jones","year":"2018"},{"key":"2024030500080493700_CIT0052","first-page":"1050","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume-title":"Ann Oncol","author":"Mato","year":"2017"},{"key":"2024030500080493700_CIT0053","first-page":"901","article-title":"Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting","volume-title":"Oncologist","author":"Hurvitz","year":"2014"},{"key":"2024030500080493700_CIT0054","first-page":"131","article-title":"First-, second-and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database","volume-title":"Lung Cancer Manag","author":"Ramsey","year":"2015"},{"key":"2024030500080493700_CIT0055","first-page":"461","article-title":"Medical costs associated with use of systemic therapy in adults with colorectal cancer","volume-title":"J Manag Care Pharm","author":"Seal","year":"2013"},{"key":"2024030500080493700_CIT0056","first-page":"e0196007","article-title":"Assessment of costs associated with adverse events in patients with cancer","volume-title":"PLoS One","author":"Wong","year":"2018"},{"key":"2024030500080493700_CIT0057","author":"National Comprehensive Cancer Network"},{"key":"2024030500080493700_CIT0058","first-page":"3869","article-title":"Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia","volume-title":"Cancer","author":"Short","year":"2015"},{"key":"2024030500080493700_CIT0059","first-page":"3586","article-title":"FDA Approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume-title":"Clin Cancer Res","author":"de Claro","year":"2015"},{"key":"2024030500080493700_CIT0060","first-page":"e462","article-title":"Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era","volume-title":"Haematologica","author":"Mato","year":"2018"},{"issue":"2","key":"2024030500080493700_CIT0061","first-page":"92","article-title":"Early intervention in asymptomatic chronic lymphocytic leukemia","volume":"19","author":"Muchtar","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"2024030500080493700_CIT0062","first-page":"174","article-title":"Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry","volume-title":"Clin Lymphoma Myeloma Leuk","author":"Mato","year":"2020"},{"key":"2024030500080493700_CIT0063","first-page":"S22","article-title":"Retrospective electronic health records study in the CancerLinQ Discovery database of treatment patterns among patients with chronic lymphocytic leukemia (Abstract PCN3)","volume-title":"Value Health","author":"Kabadi","year":"2020"},{"key":"2024030500080493700_CIT0064","first-page":"4079","article-title":"Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia\/small lymphocytic leukemia among veterans in the United States","volume-title":"Blood","author":"Yang","year":"2021"},{"key":"2024030500080493700_CIT0065","first-page":"e18065","article-title":"Economic burden of relapsed\/refractory chronic lymphocytic leukemia","volume-title":"J Clin Oncol","author":"Guerin","year":"2015"},{"key":"2024030500080493700_CIT0066","first-page":"5928","article-title":"Real-world health care utilization and costs among patients newly initiating systemic therapy for chronic lymphocytic leukemia (CLL) in the United States","volume-title":"Blood","author":"Matasar","year":"2016"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/3\/e360\/56831461\/oyad324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/3\/e360\/56831461\/oyad324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T19:08:43Z","timestamp":1709579323000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/3\/e360\/7590632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":66,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,27]]},"published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad324","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2024,1,27]]}}}